Highlights
Primary prophylaxis with pegylated granulocyte colony-stimulating factor (peg-GCSF) drastically reduced the incidence of grade 3-4 neutropenia from 38.5% in the control group to just 2.6% in the treatment group.
While 12.8% of patients in the control group experienced febrile neutropenia, zero cases were reported in the group receiving primary peg-GCSF prophylaxis.
